CSNK1A1 and myelodysplastic syndrome: Furthermore, mutation of CSNK1A1 is most commonly associated with myelodysplastic syndromes (5q deletion syndrome) and therefore CK1α has been identified as a promising therapeutic target for these patients [37,38].